Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals

  15 September 2020

The prevalence and effects of inappropriate empirical antibiotic therapy for bloodstream infections are unclear. We aimed to establish the population-level burden, predictors, and mortality risk of in-vitro susceptibility-discordant empirical antibiotic therapy among patients with bloodstream infections.

Approximately one in five patients with bloodstream infections in US hospitals received discordant empirical antibiotic therapy, receipt of which was closely associated with infection with antibiotic-resistant pathogens. Receiving discordant empirical antibiotic therapy was associated with increased odds of mortality overall, even in patients without sepsis. Early identification of bloodstream pathogens and resistance will probably improve population-level outcomes.

Author(s): Sameer S Kadri, MD Yi Ling Lai, MPH Sarah Warner, MPH Jeffrey R Strich, MD Ahmed Babiker, MBBS Emily E Ricotta, PhD Cumhur Y Demirkale, PhD John P Dekker, MD Tara N Palmore, MD Chanu Rhee, MD Prof Michael Klompas, MD Prof David C Hooper, MD John H Powers 3rd, MD Arjun Srinivasan, MD Robert L Danner, MD Jennifer Adjemian, PhD
Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!